When a company such as BLCM conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the BLCM split history from start to finish, an original position size of 1000 shares would have turned into 100 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into BLCM shares, starting with a $10,000 purchase of BLCM, presented on a split-history-adjusted basis factoring in the complete BLCM split history.

About BLCM

Bellicum Pharmaceuticals is a biopharmaceutical company focused on discovering and developing controllable cellular immunotherapies for the treatment of various forms of cancer. Co. is developing chimeric antigen receptors (CAR)-T cell therapies, which are an approach in which a patient's or donor's T cells are genetically modified to carry CARs. By incorporating its switch technologies, Co. is developing product candidates in various areas of cellular immunotherapy including BPX-601, which is designed to treat solid tumors expressing prostate stem cell antigen; and BPX-603, which is designed to target solid tumors that express the human epidermal growth factor receptor 2 antigen. According to our BLCM split history records, BLCM has had 1 split.

BLCM Split History | www.SplitHistory.com | Copyright © 2013 - 2024, All Rights Reserved